TRML Tourmaline: Net earnings per share for the last 12 months

Tourmaline Bio, Inc. (TRML) attracts leading scientists with ambitious immunology projects, creating an environment for breakthrough discoveries. The company is developing IL-1 antibodies for the therapy of severe autoimmune pathologies. The year-over-year percentage change in EPS over 12 months demonstrates profit dynamics, with the value recorded at . The absence of direct analogs in current research protects the business from price competition.

The development of patent-protected antibodies for the treatment of autoimmune pathologies creates a foundation for high future margins for Tourmaline Bio, Inc. (TRML). Net profit dynamics over a rolling year, reflected through the annual EPS growth rate over the last 12 months, allow investors to filter out market noise and determine whether the market price aligns with actual business progress, helping to distinguish a true trend reversal from a speculative impulse.